Siemens Healthineers Completes Acquisition of Varian, Strengthening its Position as a Holistic Partner in Healthcare

Siemens HealthineersSiemens Healthineers AG (Frankfurt: SHL) announced that it has successfully completed the acquisition of Varian Medical Systems, Inc. ("Varian"). The acquisition was previously announced on August 2, 2020.

"With Varian, Siemens Healthineers has the most comprehensive portfolio in the MedTech sector, which offers the company considerable potential for value creation. With a highly integrated approach, Siemens Healthineers will take the global fight against cancer to a new level," said Prof. Dr. Ralf P. Thomas, Chairman of the Supervisory Board of Siemens Healthineers AG.

"With the completion of this transaction, we are now best-positioned to take two leaps together: a leap in cancer care and a leap in our impact on healthcare overall. Together, we are establishing a strong and trusted partner capable of supporting customers and patients along the entire cancer care continuum as well as through all major clinical pathways," said Dr. Bernd Montag, CEO of Siemens Healthineers AG.

"Through the transformative combination of Varian and Siemens Healthineers, our united company will address the growing need for personalized, data-driven diagnosis and precision cancer care that enables us to fight back against globally increasing cancer rates," said Chris Toth, CEO of Varian, a Siemens Healthineers company. "By bringing together our unique and highly complementary portfolios and capabilities, we will support oncology clinicians and patients in achieving better outcomes and move even closer to achieving our vision of a world without fear of cancer."

The combined company is creating a unique, highly integrated portfolio of imaging, laboratory diagnostics, artificial intelligence and treatment for the global fight against cancer with significant potential for increased value creation. The acquisition aligns perfectly with the "Upgrading" phase of Siemens Healthineers strategy. With today's closing of the acquisition, Varian is expected to positively contribute to Siemens Healthineers adjusted basic earnings per share(1) within the first 12 months. Additionally, Siemens Healthineers aims for EBIT synergies of at least EUR 300 million per annum in fiscal year 2025.

Varian and Siemens Healthineers are building on the long-standing strategic partnership called "EnVision" to establish a comprehensive digital, diagnostic and therapeutic ecosystem that includes treatment management. With Varian, Siemens Healthineers will leverage AI-assisted analytics to advance the development and delivery of data-driven precision care and redefine cancer diagnosis, care delivery and post-treatment survivorship. Through early and accurate detection as well as more efficient diagnosis, increased treatment quality and access, Siemens Healthineers will support and accelerate Varian's mission to reduce uncertainty for cancer patients and increase the level of cancer survivorship.

Siemens Healthineers completed the first phase of its Strategy 2025 at the end of fiscal year 2019, during which the company successfully implemented its IPO and launched important product innovations such as the AI-Rad Companions. With the start of fiscal year 2020, Siemens Healthineers has entered the second phase of its "Siemens Healthineers Strategy 2025." This "Upgrading" phase will take Siemens Healthineers to the next level of profitable growth. With the acquisitions of Corindus and ECG Management Consultants, the company has already strengthened its offerings in adjacent growth areas. And, with Varian, Siemens Healthineers is well-positioned to grow in existing markets, enter adjacent fields and make new markets.

Varian's common stock ceased trading on the New York Stock Exchange prior to the opening of trading.

About Siemens Healthineers

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalising healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care to patients. In fiscal 2020, which ended on September 30, 2020, Siemens Healthineers, which has approximately 54,000 employees worldwide, generated revenue of €14.5 billion and adjusted EBIT of €2.2 billion.

1. Before purchase price allocation effects, transaction, integration, retention and restructuring costs as well as gains and losses from divestments.

Most Popular Now

AI can Help Improve Emergency Room Admis…

Generative artificial intelligence (AI), such as GPT-4, can help predict whether an emergency room patient needs to be admitted to the hospital even with only minimal training on a limited...

Philips ePatch and AI Analytics Platform…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced the successful nationwide rollout of its ambulatory cardiac monitoring service in Spain using its unique wearable ePatch...

ChatGPT Extracts Data for Ischaemic Stro…

In an ischaemic stroke, an artery in the brain is blocked by blood clots and the brain cells can no longer be supplied with blood as a result. Doctors must...

Comprehensive Bibliographic Dataset Adva…

A groundbreaking study published in Health Data Science, a Science Partner Journal, introduces a curated bibliographic dataset that aims to revolutionize the landscape of Health Artificial Intelligence (AI) research. Led...

New AI Algorithm may Improve Autoimmune …

A new advanced artificial intelligence (AI) algorithm may lead to better - and earlier - predictions and novel therapies for autoimmune diseases, which involve the immune system mistakenly attacking their...

AI Health Coach Lowers Blood Pressure an…

A new study in JMIR Cardio, published by JMIR Publications, shows that a fully digital, artificial intelligence (AI)-driven lifestyle coaching program can effectively reduce blood pressure (BP) in adults with...

Will Generative AI Change the Way Univer…

Since the launch of ChatGPT 3 in November 2022, we've been abuzz with talk of artificial intelligence: is it an unprecedented opportunity, or will it rob everyone of jobs and...

New Deep Learning Model is 'Game Ch…

Research led by the University of Plymouth has shown that a new deep learning AI model can identify what happens and when during embryonic development, from video. Published in the Journal...

Huge NHS Cloud Deals Mean Tough Question…

Opinion Article by Chris Scarisbrick, Deputy Managing Director, Sectra. The largest public cloud projects to ever take place within the NHS are beginning. Regional procurements for public cloud hosted diagnostic imaging...

AI Tech should Augment Physician Decisio…

The use of artificial intelligence (AI) in clinical health care has the potential to transform health care delivery but it should not replace physician decision-making, says the American College of...

A Three-Point Plan for Digital Delivery

Sam Shah has seen health tech policy up-close and worries that little progress has been made over the past five-years. However, he has a plan for any health and social...

Facial Thermal Imaging + AI Accurately P…

A combination of facial thermal imaging and artificial intelligence (AI) can accurately predict the presence of coronary artery disease, finds research published in the open access journal BMJ Health &...